2026-10-19T01:08:17Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/requestoai:ebyu-rdlopen.rawdatalibrary.net:ebyu/154622026-10-18T21:14:28Zopenairedrivercom_ebyu_10000col_ebyu_10001Importance of metastatic lymph node ratio in non-metastatic, lymph node-invaded colon cancer: A clinical trialIsik, ArdaPeker, KemalFirat, DenizYilmaz, BahriSayar, IlyasIdiz, OguzCakir, CoskunDemiryilmaz, IsmailYilmaz, IsmayilColonic neoplasmsLymph nodesPrognosisAge FactorsDisease-Free SurvivalFemaleHumansLymphatic MetastasisMaleMultivariate AnalysisNeoplasm InvasivenessRetrospective StudiesTumor Markers, Biologicalalpha fetoproteinC reactive proteinCA 19-9 antigencarcinoembryonic antigentumor markeradultarticlecancer mortalitycancer prognosiscancer stagingclinical trialcolon cancerdisease free survivalfollow uphumanlymph node metastasislymph node ratioBackground: The aim of this study was to evaluate the prognostic importance of the metastatic lymph node ratio for stage III colon cancer patients and to find a cut-off value at which the overall survival and disease-free survival change. Material/Methods: Patients with pathological stage III colon cancer were retrospectively evaluated for: age; preoperative values of Crp, Cea, Ca 19-9, and Afp; pathologic situation of vascular, perineural, lymphatic, and serosal involvement; and metastatic lymph node ratio values were calculated. Results: The study included 58 stage III colon cancer patients: 20 (34.5%) females and 38 (65.5%) males were involved in the study. Multivariate analysis was applied to the following variables to evaluate significance for overall survival and disease-free survival: age, Crp, Cea, perineural invasion, and metastatic lymph node ratio. The metastatic lymph node ratio (<0.25 or ≥0.25) is the only independent variable significant for overall and diseasefree survival. Conclusions: Metastatic lymph node ratio is an ideal prognostic marker for stage III colon cancer patients, and 0.25 is the cut-off value for prognosis. © Med Sci Monit, 2014.International Scientific Literature Inc.2014Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/15462https://doi.org/10.12659/msm.8908041234-1010enMedical Science Monitorinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/15462